Abstract:Cardiac remodelling is a common pathophysiological process in the development of various cardiovascular diseases, but there is still a lack of effective interventions. Tumour necrosis receptor-associated factor 7 (TRAF7) belongs to the tumour necrosis factor receptor-associated factor family and plays an important role in biological processes. Previous studies have shown that TRAF7 mutations lead to congenital defects and malformations of the heart. However, the molecular mechanisms of TRAF7 in the underlying pathogenesis of pathological cardiac hypertrophy remain unknown. We aim to study the molecular mechanisms and effects of TRAF7 in cardiac remodelling and whether it has the potential to become a therapeutic target for cardiac remodelling. The pressure overload–induced cardiac hypertrophy model in mice was established via transverse aortic constriction (TAC) surgery, and cardiomyocytes were treated with phenylephrine (PE) to induce hypertrophic phenotype. Levels of cardiac dysfunction and remodelling were measured with echocardiography and tissue or cell staining. RNA sequencing, western blot, qRT–PCR, co-immunoprecipitation, and in vivo ubiquitination assays were used to explore the molecular mechanisms. The results showed that the expression of TRAF7 increased gradually during the development of hypertrophy. Accordingly, TRAF7 significantly exacerbated the PE-induced enlargement of primary neonatal Sprague-Dawley rat cardiomyocytes, whereas TRAF7 knockdown alleviated the hypertrophic phenotype in primary cardiomyocytes. Cardiac-specific overexpression of TRAF7 accelerated hypertrophic phenotype in mice and cardiac-specific Traf7 conditional knockout mice improved hypertrophic phenotype induced by TAC. Mechanistically, TRAF7 directly interacted with apoptosis signal-regulating kinase-1 (ASK1) and promoted ASK1 phosphorylation by mediating the K63-linked ubiquitination of ASK1 in response to PE stimulation, which then promoted ASK1 activation and downstream signalling during cardiac hypertrophy. Notably, the pro-hypertrophic effect of TRAF7 was largely blocked by GS4997 in vitro and cardiac-specific Ask1 conditional knockout in vivo . In summary, we identified TRAF7 as an essential regulator during cardiac hypertrophy, and modulation of the regulatory axis between TRAF7 and ASK1 could be a novel therapeutic strategy to prevent this pathological process. A schematic diagram of the molecular mechanisms underlying tumour necrosis receptor-associated factor 7 (TRAF7)-regulated cardiac hypertrophy. Under hypertrophic stimulation, reactive oxygen specices (ROS)-triggered TRAF7 expressing binds to the apoptosis signal-regulating kinase-1 (ASK1) through its WD40 repeats domain and applies the ring domain to promote the ubiquitination of lys1064 in ASK1 via the K63 ubiquitin chain, thereby promoting ASK1 phosphorylation and then activating JNK/p38 axis in cardiomyocytes.

The E3 ubiquitin ligase TRIM31 plays a critical role in hypertensive nephropathy by promoting proteasomal degradation of MAP3K7 in the TGF-β1 signaling pathway

Trim21 modulates endoplasmic reticulum-associated degradation and sensitizes cancer cells to ER stress-induced apoptosis by inhibiting VCP/Npl4/UFD1 assembly

The E3 ubiquitin ligase TRIM39 modulates renal fibrosis induced by unilateral ureteral obstruction through regulating proteasomal degradation of PRDX3

E3 ubiquitin ligase TRIM31: A potential therapeutic target

The Expression of TRIM6 Activates the mTORC1 Pathway by Regulating the Ubiquitination of TSC1-TSC2 to Promote Renal Fibrosis

The E3 Ligase TRIM16 Is a Key Suppressor of Pathological Cardiac Hypertrophy

E3 ubiquitin ligase TRIM31 alleviates dopaminergic neurodegeneration by promoting proteasomal degradation of VDAC1 in Parkinson's Disease model

TRIM31 confers protection against nonalcoholic steatohepatitis by deactivating MAP3K7

TRIM65 deficiency alleviates renal fibrosis through NUDT21-mediated alternative polyadenylation

E3 Ubiquitin Ligase TRIM31 Alleviates Dopaminergic Neurodegeneration by Promoting Proteasomal Degradation of VDAC1 in Parkinson’s Disease Model

Smad7 inhibits AngII-mediated hypertensive nephropathy in a mouse model of hypertension.

Disruption of Smad7 Promotes ANG II-Mediated Renal Inflammation and Fibrosis Via Sp1-TGF-β/Smad3-NF.κB-Dependent Mechanisms in Mice

E3 Ligase TRIM25 Ubiquitinates RIP3 to Inhibit TNF Induced Cell Necrosis

The E3 ubiquitin ligase TRIM31 is involved in cerebral ischemic injury by promoting degradation of TIGAR

Smad3 mediates ANG II-induced hypertensive kidney disease in mice.

TRIM46 upregulates Wnt/β-catenin signaling by inhibiting Axin1 to mediate hypoxia-induced epithelial–mesenchymal transition in HK2 cells

Mutual regulation between TRIM21 and TRIM8 via K48-linked ubiquitination

The E3 ligase Trim63 promotes podocyte injury and proteinuria by targeting PPARα to inhibit fatty acid oxidation

E3 Ubiquitin Ligase TRIM9 Ubiquitin Modified-Beclin1 Regulates Autophagy to Relieve Myocardial Ischemia Reperfusion Injury

Cardiac tumour necrosis factor receptor-associated factor 7 mediates the ubiquitination of apoptosis signal-regulating kinase 1 and aggravates cardiac hypertrophy

The E3 ubiquitin-protein ligase Trim31 alleviates non-alcoholic fatty liver disease by targeting Rhbdf2 in mouse hepatocytes